MSD Exec Says Ranbaxy Issue Unlikely To Taint India Drug Makers In U.S.
This article was originally published in PharmAsia News
Executive Summary
Merck Sharp & Dohme's emerging-markets president, Kevin Ali, says the U.S. market is not likely to shun drugs made in India just because of the scandal involving Ranbaxy Laboratories.